Nucleic Acid Testing: A Vehicle for Advancing Personalized Medicine

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction to NAT - A Central Technology
  • Driving the Evolution to Personalized Medicine
  • Affecting Drug Discovery and Approval
  • Leading the Molecular Diagnostic Assay Technologies
  • Scope of the Report
• The NAT Toolbox: Technologies for Now and the Future
• Therapeutic Focus of the NAT Market
  • Blood Screening and Infectious Diseases
    • Testing for Sexually Transmitted Infections
    • Hospital-Acquired Infections Testing
    • HIV Drug Resistance Testing
    • Infectious Respiratory Diseases
  • Oncology
    • Hereditary Risk Assays
    • Early Detection Assays
    • Targeted Therapy Assays
    • Assays for Cancer Prognosis
    • Assays Guiding Treatment Options
• Company Leaders in NAT
• Future Trends
  • Applications That Will Drive the NAT Market for the Foreseeable Future
  • Leading Companies in NAT Will Drive Growth Through Acquisitions and Licensing
  • NAT Assays Are High Value, but Tests Need to Demonstrate Cost-Effectiveness

Sidebar

• Using Discovery Tools to Shape Future NAT Oncology Assays

Tables

• 1. The Nucleic Acid Testing Toolbox
• 2. Validated Genomic Biomarkers for Select Approved Agents
• 3. Select Nucleic Acid Testing Leaders, by Market Segment
• 4. Select Acquisitions in NAT, November 2007-December 2008
• Appendix A. Select Licensing and Collaboration Activities in NAT, November 2007-December 2008

Figures

• 1. NAT Alliances in 2008, by Therapeutic Area
• 2. Algorithm for the Diagnosis of Chronic Hepatitis C
• 3. Cancer Molecular Targets